In a separate set of experiments using breast cancer samples, we determined that PBMCs will infiltrate the tumor fragment at a rate of 1%–2% of the total tumor CD45+ population, which becomes more variable when PD-1 checkpoint inhibitors are added (data not shown). This evidence concerns the gene PTPRC and breast carcinoma.